Saturday 17 October 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
6.08
0.32
−5.00%
Follow GYRE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | 4 | 5 |
+8 more TTM periods Free account |
| (11.75%) | (5.27%) | 6.37% | 3.53% | ||
| (9.08%) | (4.36%) | 2.91% | 2.93% | ||
ROIC |
(8.51%) | (0.10%) | 7.50% | 6.16% | |
Return on Tangible Assets |
(13.24%) | (6.66%) | 3.28% | 3.92% | |
Average Days of Receivables |
87.83 | 71.70 | 98.02 | 86.45 | |
Free Cash Flow per Share |
(0.07) | 0.03 | (0.01) | 0.02 | |
Free Cash Flow |
(7.12) | 3.07 | (0.88) | 1.51 | |
Capital Expenditures |
(2.19) | (1.25) | (1.89) | (2.37) | |
| Other line items | |||||
Cash ROIC |
(2.97%) | 1.64% | (0.31%) | 0.76% | |
Accounts Receivable Turnover |
4.40 | 5.40 | 4.16 | 4.70 | |
Accounts Payable Turnover |
10.42 | 29.71 | 7.51 | 11.29 | |
Inventory Turnover |
0.67 | 0.60 | 0.66 | 0.64 | |
Average Days of Payables |
66.28 | 16.82 | 89.97 | 41.84 | |
Days of Inventory on Hand |
612.78 | 720.73 | 685.45 | 666.33 | |
Tax Rate |
0.28 | (7.58) | (0.32) | (0.30) | |
Research and Development Expense of Revenue |
24.16% | 14.82% | 11.75% | 15.90% | |
Selling, General and Administrative Expense of Revenue |
77.90% | 78.21% | 73.75% | 72.79% | |
Share Based Compensation of Revenue |
8.48% | 7.89% | 6.14% | 2.84% | |
Interest Coverage |
(6.52) | — | — | — | |
Operating CF/Net income |
0.31 | (0.68) | 0.20 | 0.93 | |
Depreciation/Fixed assets |
0.12 | 0.11 | 0.09 | 0.10 | |
Capex/Depreciation |
(0.69) | (0.47) | (0.75) | (1.02) | |
Revenue per Share |
1.16 | 1.28 | 1.30 | 1.21 | |
Operating CF per Share |
(0.05) | 0.05 | 0.01 | 0.04 | |
Capex per Share |
(0.02) | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.02 |
Columns are period end dates